VINC

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.

CEO: Raquel E. Izumi
IPO Date: May 27, 2020

Market Data

Open: $0.0127
High: $0.0127
Low: $0.0127
Volume: 328
Avg Volume: 5.1K
52W High: $1.43
52W Low: $0.001

Valuation

Market Cap: $66k
Enterprise Value: $-4.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-26M
Revenue: $0
Net Income: $-30M
Cash: $5.0M
Debt: $0

Events

EarningsAug 7